Cargando…

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

Multiple myeloma (MM) is a B cell neoplasia characterized by clonal plasma cell (PC) proliferation. Minimal residual disease monitoring by multi-parameter flow cytometry is a powerful tool for predicting treatment efficacy and MM outcome. In this study, we compared CD antigens expression between nor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alaterre, Elina, Raimbault, Sebastien, Goldschmidt, Hartmut, Bouhya, Salahedine, Requirand, Guilhem, Robert, Nicolas, Boireau, Stéphanie, Seckinger, Anja, Hose, Dirk, Klein, Bernard, Moreaux, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716778/ https://www.ncbi.nlm.nih.gov/pubmed/29228738 http://dx.doi.org/10.18632/oncotarget.22131

Ejemplares similares

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

Responses of CD27(+)CD38(+) plasmablasts, and CD24(hi)CD27(hi) and CD24(hi)CD38(hi) regulatory B cells during primary dengue virus 2 infection
por: Lei, Chenshuang, et al.
Publicado: (2021)

Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36
por: Xie, Xiulong, et al.
Publicado: (2023)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Dysfunction of CD19(+)CD24(hi)CD27(+) B regulatory cells in patients with bullous pemphigoid
por: Liu, Zhenfeng, et al.
Publicado: (2018)

Plasma cells are not restricted to the CD27+ phenotype: characterization of CD27-CD43+ antibody-secreting cells
por: Covens, Kris, et al.
Publicado: (2023)

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies
por: Tanase, Cristiana, et al.
Publicado: (2020)

Decrease in Proportion of CD19(+)CD24(hi)CD27(+) B Cells and Impairment of Their Suppressive Function in Graves’ Disease
por: Zha, Bingbing, et al.
Publicado: (2012)

The nature of circulating CD27(+)CD43(+) B cells
por: Perez-Andres, Martin, et al.
Publicado: (2011)

CD27(+) microparticle interactions and immunoregulation of CD4(+) T lymphocytes
por: Cagnet, Léonie, et al.
Publicado: (2023)

P802: CD70/CD27 SIGNALING PROMOTES THE EXPANSION OF CLONAL PLASMA CELL SUBSETS IN MULTIPLE MYELOMA
por: Forster, Stefan, et al.
Publicado: (2023)

Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Accumulation of synovial fluid CD19(+)CD24(hi)CD27(+) B cells was associated with bone destruction in rheumatoid arthritis
por: Guo, Xiaofeng, et al.
Publicado: (2020)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

CD27(-)CD38(low)CD21(low) B-Cells Are Increased in Axial Spondyloarthritis
por: Wilbrink, Rick, et al.
Publicado: (2021)

Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma
por: Gamache, Awndre, et al.
Publicado: (2023)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

The role of CD36 in cardiovascular disease
por: Shu, Hongyang, et al.
Publicado: (2020)

CD36 Signaling in Diabetic Cardiomyopathy
por: Zhang, Xudong, et al.
Publicado: (2021)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)
por: Leite, Luiz Arthur Calheiros, et al.
Publicado: (2012)

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
por: Lo, Tsun-Ho, et al.
Publicado: (2019)

Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(−) T-cells
por: Neuber, Brigitte, et al.
Publicado: (2017)

Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?
por: Tanase, Cristiana, et al.
Publicado: (2022)

Impact of the interaction between the polymorphisms and hypermethylation of the CD36 gene on a new biomarker of type 2 diabetes mellitus: circulating soluble CD36 (sCD36) in Senegalese females
por: Touré, Maïmouna, et al.
Publicado: (2022)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature
por: Erhart, Friedrich, et al.
Publicado: (2018)

Inhibition of Glycogen Synthase Kinase 3β Increases the Proportion and Suppressive Function of CD19(+)CD24(hi)CD27(+) Breg Cells
por: Li, Jinyang, et al.
Publicado: (2020)

CD4(+)CD25(+) cells in multiple myeloma related renal impairment
por: Huang, Hongdong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4k27beu73hu0go6k3c01uj8sra